Media & Press Releases

Nearly 400 pharmaceutical professionals weigh in on challenges and opportunities with introducing technological innovation, citing economic factors and regulatory concerns as key barriers The International Society for Pharmaceutical Engineering (ISPE...

Judges Name Four Category Winners Plus Two Honorable Mentions with Plans to Unveil Overall FOYA Winner at the 2024 ISPE Annual Meeting & Expo, 13 October, in Orlando, Florida, USA ISPE recently announced category winners for its 2024 Facility of the...

Maria Löflund, site head at Takeda Manufacturing Austria AG, has provided insights into the implementation of the latest Annex 1 update during the 2024 ISPE Aseptic Conference in Vienna, Austria. The update is aimed at modernizing aseptic...

The 2024 ISPE Europe Annual Conference will occur on 16-18 April in Lisbon, Portugal, and virtually. ISPE has announced a regulatory focus with speakers from global health authorities and industry leaders at the 2024 ISPE Europe Annual Conference...

The 2024 Facility of the Year Awards (FOYA) submission finalists are announced at the 2024 ISPE Aseptic Conference, taking place in Vienna, Austria, and virtually.  ISPE is pleased to announce the 2024 Facility of the Year Awards (FOYA) submission...

In an interview with Bioprocess Online, Diane Hustead, Executive Director, Regulatory Affairs, Merck & Co., Inc., and current chair of the ISPE Drug Shortages Initiative Team, discusses updates to the 2023 ISPE Drug Shortages Prevention Model. The...

The 2024 ISPE Aseptic Conference will take place 12-13 March 2024 in Vienna, Austria, and virtually. ISPE has announced representative participation from health authorities around the world at the 2024 ISPE Aseptic Conference. Featured spea kers...

Industry experts have shared insights on 2024 predictions for the pharmaceutical industry with Pharma Manufacturing. In part two of this series, ISPE President and CEO Thomas Hartman highlights that accountability and authenticity will be key...

ISPE President and CEO Thomas Hartman provides insights on how AI may impact the biotech industry in 2024. Thomas observes that the meteoric rise of AI took every industry by surprise in 2023. In 2024, he notes, “companies will have more time to take...

ISPE President and CEO Thomas Hartman calls attention to the importance of addressing drug shortages in 2024 in part three of an article, “Scrip Asks…What Does 2024 Hold for Biopharma?” The article features expert insights on manufacturing and supply...